Ayvakit (avapritinib) — Medica
Myeloid/lymphoid neoplasms with eosinophilia and PDGFRA D842V mutation
Initial criteria
- Patient is age ≥ 18 years
- Patient has eosinophilia
- Tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation
Approval duration
1 year